JMP Securities Reiterates Market Outperform on LAVA Therapeutics, Maintains $6 Price Target
Portfolio Pulse from richadhand@benzinga.com
JMP Securities analyst Reni Benjamin reiterated a Market Outperform rating on LAVA Therapeutics (NASDAQ:LVTX) and maintained a $6 price target.
June 15, 2023 | 12:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities analyst Reni Benjamin reiterated a Market Outperform rating on LAVA Therapeutics (NASDAQ:LVTX) and maintained a $6 price target.
The reiteration of the Market Outperform rating and maintenance of the $6 price target by JMP Securities analyst Reni Benjamin indicates a positive outlook for LAVA Therapeutics (LVTX) in the short term. This news is directly related to LVTX and is important for investors as it reflects the analyst's confidence in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100